May 26, 2006
FDA Licenses New Vaccine to Reduce Risk of Shingles in Older Americans
Zostavax, a live virus vaccine, is given as a single injection is recommended for use in people 60 years of age and older.

Zostavax was studied in 38,000 individuals living in the United States who were 60 years of age and older. Researchers found that, overall, in those ages 60 and above the vaccine reduced the occurrence of shingles by about 50%. For individuals aged 60-69 it reduced occurrence by 64%. FDA